The Warburg effect has been explained for a century as metabolic reprogramming, an active choice by cancer cells to run aerobic glycolysis for biosynthetic benefit. This paper argues the opposite. Drawing on established findings from five separate literatures (cycling hypoxia in tumors, ischemia-reperfusion injury at Complex I, mtDNA mutation accumulation in cancer, succinate-driven HIF-1α stabilization, and Complex I assembly defects as drivers of aerobic glycolysis), the argument integrates these into a single continuous mechanism. Cycling ischemia-reperfusion generates repeated ROS bursts that damage both ETC proteins and mtDNA. Compensatory replication from damaged templates compounds the damage into a one-way ratchet. Progressive structural loss of Complex I drives succinate accumulation, HIF-1α stabilization in normoxia, permanent PDK upregulation, and the Warburg phenotype as a structural endpoint. Complex II, entirely nuclear-encoded with histone protection and full repair access, remains structurally intact, providing a specific falsifiable prediction. The activity ratio of the mtDNA-dependent ETC complexes (I, III, IV) to Complex II should decline monotonically with disease stage. Each step of the chain is supported by prior empirical work. The contribution here is the architectural integration, the identification of the ratchet as the cumulative mechanism, the identification of the complex-activity-ratio pattern as the testable structural signature, and the therapeutic implication. If the Warburg phenotype is structural failure rather than reprogramming, the correct therapeutic direction is to push more fuel through the broken chain, not restrict it. This inverts the prevailing therapeutic strategy that treats cancer as a mitochondrial metabolic disease.
Andrew Hooks (Thu,) studied this question.